ImmunityBio, Inc.
IBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2,270.6% | 159.2% | -74.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,334.2% | -58,239.5% | -146,374.2% | -35,361.9% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$1 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$0 | -$0 |
| % Margin | -2,804.8% | -93,761.4% | -173,569.6% | -37,129.6% |
| EPS | -0.59 | -1.15 | -1.04 | -0.89 |
| % Growth | 48.7% | -10.6% | -16.9% | – |
| EPS Diluted | -0.62 | -1.15 | -1.04 | -0.89 |
| Weighted Avg Shares Out | 1 | 1 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,793.4% | -76,955.5% | -146,617.1% | -34,341.8% |